Dyne Therapeutics prices upsized $350M public offering at $18.44/share

Dyne Therapeutics, Inc.

Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.
Underwriters granted 30-day option for additional 2,847,071 shares.
Net proceeds estimated at ~$328.5M ($377.9M if option exercised).
Also borrowed $50M second tranche under Hercules Loan Agreement.
Cash runway extended into Q1 2028 with combined resources.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.